M&R Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

M&R Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$158K	Hold	150	–	–	0.03%	151
2024 Q2	$158K	Hold	150	–	–	0.04%	147
2024 Q1	$145K	Hold	150	–	–	0.04%	150
2023 Q4	$132K	Hold	150	–	–	0.03%	176
2023 Q3	$123K	Hold	150	–	–	0.03%	169
2023 Q2	$108K	Hold	150	–	–	0.03%	181
2023 Q1	$123K	Hold	150	–	–	0.03%	168
2022 Q4	$108K	Sell	150 -90	-38%	-$66.4K	0.03%	182
2022 Q3	$165K	Hold	240	–	–	0.05%	149
2022 Q2	$141K	Hold	240	–	–	0.04%	166
2022 Q1	$167K	Buy	240 +200	+500%	+$127K	0.04%	159
2021 Q4	$25K	Hold	40	–	–	0.01%	286
2021 Q3	$24K	Hold	40	–	–	0.01%	289
2021 Q2	$22K	Hold	40	–	–	0.01%	299
2021 Q1	$18K	Buy	40 +15	+60%	+$7.3K	﹤0.01%	294
2020 Q4	$12K	Buy	+25	New	+$13.5K	﹤0.01%	338

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

M&R Capital Management's REGN Position: Q3 2024 in Review

M&R Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2024 at 150 shares worth $158K. The position accounts for 0.03% of the portfolio, ranked #151.

M&R Capital Management first reported a position in REGN in Q4 2020 and has held it in 16 quarters since. The position peaked at $167K in Q1 2022. 1,391 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

M&R Capital Management held 150 shares of Regeneron Pharmaceuticals worth $158K as of Q3 2024.
M&R Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2024.
Regeneron Pharmaceuticals made up 0.03% of M&R Capital Management's portfolio in Q3 2024, its #151 holding.
M&R Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
M&R Capital Management's Regeneron Pharmaceuticals position peaked at $167K in Q1 2022.
1,391 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on M&R Capital Management's 13F filing for Q3 2024, filed 2 Oct 2024.